<DOC>
	<DOCNO>NCT00699036</DOCNO>
	<brief_summary>The purpose study evaluate efficacy rosiglitazone alone compare rosiglitazone plus metformin rosiglitazone plus losartan treatment biopsy proven nonalcoholic steatohepatitis ( NASH ) . This study design answer question : difference efficacy ( measure histopathology insulin resistance ) three different therapeutic modality use treat NASH ?</brief_summary>
	<brief_title>Rosiglitazone Versus Rosiglitazone Metformin Versus Rosiglitazone Avandia Treatment Nonalcoholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>1 . Patients 1870 year old 2 . Negative urine pregnancy test females 3 . History elevate liver associate enzyme ( ALT &gt; 40 ) 4 . Liver biopsy within 1 year screening study show histopathologic finding consistent NASH 1 . ALT great three time normal 2 . NYHA class 3 4 heart failure 3 . Any congestive heart failure patient insulin 4 . Patients one 3 study drug within past 3 month prior enrollment 5 . Alcohol consumption &gt; 20 gm/day female &gt; 30 gm/day male 6 . Evidence coexistent chronic liver disease include viral hepatitis , Wilson 's disease , autoimmune hepatitis , hemochromatosis , primary biliary cirrhosis , primary sclerosing cholangitis 7 . Serum creatinine initial screening great 1.4 8 . Known hypersensitivity rosiglitazone , metformin , losartan 9 . Known history diabetic ketoacidosis 10 . Female breastfeed 11 . Insulin dependent diabetic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>nonalcoholic steatohepatitis ( NASH )</keyword>
	<keyword>fatty liver</keyword>
	<keyword>insulin resistance</keyword>
</DOC>